Mycophenolate Mofetil (MMF): A Long-Term Data Evaluation

This study is not yet open for participant recruitment.

Verified by University of California, Los Angeles, April 2005

First Received: September 12, 2005 Last Updated: July 11, 2006 History of Changes

Sponsors and Collaborators:	University of California, Los Angeles Novartis
Information provided by:	University of California, Los Angeles
ClinicalTrials.gov Identifier:	NCT00203671

Purpose

The purposes of this study are:

To review past clinical use of mycophenolate mofetil (MMF) in kidney transplant patients;
To discover why doses were modified and how those modifications affected the survival and health of the transplanted kidney; and
To determine whether, therefore, the side effects of MMF that result in dose alterations are related to outcome.

Condition
Kidney Diseases

Study Type:	Observational
Study Design:	Natural History, Longitudinal, Defined Population, Retrospective Study
Official Title:	Mycophenolate Mofetil (MMF): A Long-Term Data Evaluation

Resource links provided by NLM:

MedlinePlus related topics: Kidney Transplantation

Drug Information available for: Mycophenolate mofetil hydrochloride Mycophenolate Mofetil

U.S. FDA Resources

Further study details as provided by University of California, Los Angeles:

Estimated Enrollment:

900

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Renal transplant recipients of either a cadaveric or living donor kidney.
18 years of age or older.

Exclusion Criteria:

Multiple organ transplant recipients.
Prior kidney transplant recipients.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00203671

Contacts

Contact: Alan H Wilkinson, MD	(310) 794-1781	awilkinson@mednet.ucla.edu
Contact: Vincent Basehart	(310) 794-8558	vbasehart@mednet.ucla.edu

Sponsors and Collaborators

University of California, Los Angeles

Novartis

Investigators

Principal Investigator:	Alan H Wilkinson, MD	University of California, Los Angeles
Study Chair:	Ralph Barbeito, Ph.D.	Novartis Pharmaceuticals

More Information

No publications provided

Study ID Numbers:	04-05-018-01
Study First Received:	September 12, 2005
Last Updated:	July 11, 2006
ClinicalTrials.gov Identifier:	NCT00203671 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by University of California, Los Angeles:

renal
transplant
kidney
rejection

MMF
Mycophenolate Mofetil
outcomes
Kidney Transplantation

Study placed in the following topic categories:

Anti-Bacterial Agents
Immunologic Factors
Urologic Diseases
Mycophenolic Acid

Mycophenolate mofetil
Kidney Diseases
Immunosuppressive Agents

Additional relevant MeSH terms:

Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Physiological Effects of Drugs
Mycophenolic Acid
Enzyme Inhibitors
Antibiotics, Antineoplastic

Immunosuppressive Agents
Pharmacologic Actions
Urologic Diseases
Therapeutic Uses
Mycophenolate mofetil
Kidney Diseases

ClinicalTrials.gov processed this record on September 11, 2009